Abstract
Vaccination against tuberculosis (TB) by intracutaneous inoculation with bacille Calmette-Guerin (BCG) is widely used and generally well tolerated [1]. In Japan, the BCG Tokyo-172 substrain is administrated percutaneously by the multipuncture method at approximately 3 months of age in accordance with the national vaccination program guidelines. This vaccine has shown favorable characteristics of good efficacy and rare side reactions [2]. However, we report two cases of BCG Tokyo-172-related osteomyelitis without any underlying immunodeficiency disorders and discuss the key indicators for diagnosing BCG osteomyelitis (BCGO).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
